company background image
VIRI

Virios TherapeuticsNasdaqCM:VIRI Stock Report

Market Cap

US$40.1m

7D

-2.8%

1Y

n/a

Updated

04 Dec, 2021

Data

Company Financials +
VIRI fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

VIRI Stock Overview

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.

Price History & Performance

Summary of all time highs, changes and price drops for Virios Therapeutics
Historical stock prices
Current Share PriceUS$4.81
52 Week HighUS$16.71
52 Week LowUS$4.00
Beta0
1 Month Change-17.64%
3 Month Change-15.32%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-71.21%

Recent News & Updates

Nov 02
Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Jul 19
Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

VIRIUS BiotechsUS Market
7D-2.8%-4.1%-2.7%
1Yn/a-1.4%16.6%

Return vs Industry: Insufficient data to determine how VIRI performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how VIRI performed against the US Market.

Price Volatility

Is VIRI's price volatile compared to industry and market?
VIRI volatility
VIRI Average Weekly Movement11.6%
Biotechs Industry Average Movement8.8%
Market Average Movement6.1%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: VIRI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: VIRI's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20123Greg Duncanhttps://www.virios.com

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020.

Virios Therapeutics Fundamentals Summary

How do Virios Therapeutics's earnings and revenue compare to its market cap?
VIRI fundamental statistics
Market CapUS$40.07m
Earnings (TTM)-US$17.95m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VIRI income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$17.95m
Earnings-US$17.95m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.15
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did VIRI perform over the long term?

See historical performance and comparison

Valuation

Is Virios Therapeutics undervalued compared to its fair value and its price relative to the market?

2.12x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VIRI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VIRI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VIRI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: VIRI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VIRI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VIRI is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (2.6x).


Future Growth

How is Virios Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-28.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VIRI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VIRI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VIRI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if VIRI's revenue is forecast to grow faster than the US market.

High Growth Revenue: VIRI is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VIRI's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Virios Therapeutics performed over the past 5 years?

-300.3%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: VIRI is currently unprofitable.

Growing Profit Margin: VIRI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if VIRI's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare VIRI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VIRI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: VIRI has a negative Return on Equity (-95.07%), as it is currently unprofitable.


Financial Health

How is Virios Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: VIRI's short term assets ($20.1M) exceed its short term liabilities ($1.2M).

Long Term Liabilities: VIRI has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: VIRI is debt free.

Reducing Debt: VIRI had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VIRI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VIRI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 85.9% each year


Dividend

What is Virios Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VIRI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VIRI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VIRI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VIRI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VIRI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Greg Duncan (56 yo)

1.67yrs

Tenure

US$3,669,169

Compensation

Mr. Greg Duncan serves as Chief Executive Officer at Virios Therapeutics, Inc., (formerly Virios Therapeutics, LLC) since April 01, 2020 and serves as its Chairman. Mr. Duncan serves as the member of the b...


CEO Compensation Analysis

Compensation vs Market: Greg's total compensation ($USD3.67M) is above average for companies of similar size in the US market ($USD567.08K).

Compensation vs Earnings: Insufficient data to compare Greg's compensation with company performance.


Leadership Team

Experienced Management: VIRI's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: VIRI's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: VIRI only recently listed within the past 12 months.


Top Shareholders

Company Information

Virios Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Virios Therapeutics, Inc.
  • Ticker: VIRI
  • Exchange: NasdaqCM
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$40.069m
  • Shares outstanding: 8.33m
  • Website: https://www.virios.com

Number of Employees


Location

  • Virios Therapeutics, Inc.
  • 44 Milton Avenue
  • Alpharetta
  • Georgia
  • 30009
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/04 00:13
End of Day Share Price2021/12/03 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.